Members of a youth-led peer program launched in part by Johnson & Johnson that aims to reduce HIV infections among young women in sub-Saharan Africa
Share
Latest News
365 Days of Caring: 13 Ways Johnson & Johnson Helped Progress Health for Humanity in 2018
365 Days of Caring: 13 Ways Johnson & Johnson Helped Progress Health for Humanity in 2018
Share
From a $10 million pledge to UNICEF in support of health workers to promising news about a preventive HIV vaccine regimen, the company’s new 2018 Health for Humanity Report details how Johnson & Johnson is dedicated to creating a better future for everyone, everywhere.

ealth should be accessible to all.

And yet every day people and communities around the globe face complex diseases and environmental challenges.

Which is why, as the world’s largest and most broadly based healthcare company, Johnson & Johnson is committed to using its reach and size to help improve the health of people around the world and the environment in which they live.

From efforts to help fight and prevent disease to the development of more sustainable products, the company’s newly released 2018 Health for Humanity Report details the progress the company made last year toward meeting the Health for Humanity Goals it has pledged to achieve by 2020, as well as the U.N.’s 2030 Sustainable Development Goals.

“At Johnson & Johnson, we know that changing the trajectory of health of humanity requires dedication and commitment on many fronts,” says Alex Gorsky Alex Gorsky,Chairman and CEO, Johnson & Johnson, Chairman and CEO, Johnson & Johnson. "We’re proud to share this year’s Health for Humanity Report, which details the progress we’ve made in improving our environmental, social and governance practices—and we’re committed to finding even more ways to create a healthier society. It’s not just part of our business model, it’s a fundamental tenet of our values as a company.”

Month by month, effort by effort, learn about just some of the ways Johnson & Johnson worked last year to make the world a healthier place—and ensure it becomes even healthier for each generation to come.

  • Screenshot of the Cancer.com homepage
    January

    Cancer.com Debuts

    When you receive a cancer diagnosis, it’s natural to want to go online to get more information—and easy to get overwhelmed. That’s why Janssen Oncology, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, launched Cancer.com: a one-stop digital destination that's tailored to patients and their caregivers based on several different types of cancer and where they are in their journey. The goal? Help guide them through many of the decisions they’ll have to make when faced with the disease.

    Read More
  • The Johnson & Johnson Institute on Wheels in India The Johnson & Johnson Institute on Wheels
    March

    The Johnson & Johnson Institute on Wheels Hits the Road

    With a population of over 1.3 billion—and growing—it’s not always easy for many people in India to get access to the medical care they need. In fact, there are only six physicians and 13 nurses for every 10,000 people in the country.

    The mobile Johnson & Johnson Institute on Wheels, which got rolling last March, is helping to train healthcare professionals—doctors, nurses and paramedical staff—over the next five years in service of providing better outcomes for patients across the country. So far, it has reached 73 towns and 113 medical institutions, training over 10,500 healthcare professionals.

    Read More
  • A sleeping baby
    May

    A Project to Help Develop Better Treatments for Babies Is Born

    In May 2018, Johnson & Johnson joined forces with academic and industry partners to form a European network called conect4children that’s helping facilitate pediatric clinical trials with the hope of developing better treatments for babies, kids and young people.

    Read More
  • JLABS @ NYC JLABS @ NYC
    June

    JLABS @ NYC Opens Its Doors

    In the seven years since its inception, Johnson & Johnson Innovation, JLABS— an incubator that helps healthcare entrepreneurs bring their innovations to life by providing mentoring and resources like lab space—has supported more than 500 start-ups at its nine locations around the world, from California to Belgium. In June 2018, JLABS @ NYC, which will focus on biotech, pharmaceutical, medical device and consumer health innovations, was added to the roster.

    And one healthcare challenge in particular got an R&D boost this month, too, when the Janssen Pharmaceutical Companies of Johnson & Johnson initiated a Phase 1b/2 clinical development program as part of a collaboration with Legend Biotech USA to develop a potential chimeric antigen receptor T cell therapy (CAR-T) for multiple myeloma, an incurable blood cancer.

    Read More
  • Imbokodo trial logo
    July

    Promising Early Results Come in for Janssen's HIV Vaccine

    In 2017, Johnson & Johnson and global partners launched the Imbokodo study to see if a new preventive vaccine regimen might be able to help reduce HIV infections in women in sub-Saharan Africa—a population at higher risk of contracting the disease. In July 2018, early stage data from the APPROACH study was published in The Lancet, suggesting that the regimen induced a robust immune response to the virus in humans. Just a few weeks later, the first long-term immune response results from APPROACH were presented at the AIDS 2018 conference.

    Read More
  • The Kagera River in Rwanda Rwanda
    August

    A Potentially Lifesaving Mental Health Program Launches in Rwanda

    Another important company commitment: providing resources to those living with mental illness. Due in part to a lack of local support, up to 85% of people with serious mental disorders living in low- and middle-income countries haven’t received treatment for their conditions, according to the World Health Organization (WHO).

    To help address this unmet need in Rwanda, Johnson & Johnson announced a partnership in August with the Government of Rwanda and other organizations to improve access to quality mental healthcare in the country, including training community healthcare workers—with hopes to eventually expand the program throughout sub-Saharan Africa. One focus of the partnership: creating a platform for patients with schizophrenia to have access to treatment with long-acting injectables, which may be particularly helpful to those who don't have frequent access to medical care.

    Read More
  • Paul Stoffels, Chief Scientific Officer, Johnson & Johnson, on stage at the 2018 Global Citizen Festival Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson, at the 2018 Global Citizen Festival
    September

    The Health for All Alliance Is Formed

    At the 2018 Global Citizen Festival in New York City, Johnson & Johnson announced that it was joining the WHO, government partners and other organizations to create the Health for All Alliance, which will work to ensure healthcare workers worldwide can access the skills and digital tools they need to help save lives.

    And through a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute at the University of Oxford, Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced it will work on developing novel vaccines to protect against three potential global threats for which no vaccines currently exist: the Middle East Respiratory Syndrome (MERS) virus, the brain-damaging Nipah virus, and the Lassa virus, which causes hemorrhagic fever.

    Read More
  • A nurse making a young patient smile
    October

    The Johnson & Johnson Nurses Innovate QuickFire Challenge Is Announced

    The company’s inaugural Nurses Innovate QuickFire Challenge invited nurses to submit concepts for life-changing devices, health technologies, protocols or treatment approaches that have the potential to transform human health. During National Nurses Week in May 2019, two awardees were announced, with each receiving $50,000 in grants, plus ongoing mentoring and coaching from Johnson & Johnson Innovation, JLABS, to help bring their solutions to life.

    Johnson & Johnson made an important commitment to the planet in October, too. Plastic waste is one of the most urgent environmental issues of our time, which is why Johnson & Johnson Consumer signed the New Plastics Economy Global Commitment—alongside more than 250 other companies, governments and NGOs—pledging to use more recycled materials in its packaging, reduce reliance on single-use packages, and ensure that 100% of its plastic packaging be reusable, recyclable or compostable by 2025.

    Read More
  • Alex Gorsky, Johnson & Johnson Chairman and CEO, and Caryl Stern, president and CEO of UNICEF USA, on World Children's Day Johnson & Johnson Chairman and CEO Alex Gorsky and Caryl Stern, president and CEO, UNICEF USA, announce the company's pledge
    November

    UNICEF Receives a $10 Million Pledge

    Johnson & Johnson has had a strong global partnership with UNICEF for over 30 years. In November 2018, the company strengthened that bond through a $10 million pledge to support health workers in delivering care to newborns, children and mothers around the world, including among Indigenous communities in Vietnam and the Philippines.

    Read More
  • Two smiling young girls
    December

    A Treatment for Intestinal Worm Infections Helps Kids Around the Globe

    Soil-transmitted helminths (STH), also known as intestinal worm infections, affect approximately 1.5 billion people worldwide. Kids are particularly vulnerable to STH, which can often lead to malnutrition and even impaired cognitive development. So in December, Janssen submitted a prequalification dossier to the WHO for a pediatric formulation of a worm-fighting medication that can either be chewed or mixed with a small amount of water to form a soft mass that's easier for very young children to swallow.

    In April 2019, the WHO prequalified the formulation, which will support the introduction of this medication in STH treatment programs in high-burden countries. Johnson & Johnson will soon begin distributing it as part of the 200 million doses of the treatment it’s committed to donating around the world annually.

    Read More
You can read about even more strides Johnson & Johnson made toward its goals last year by accessing the full report.

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue
欧美成人视频